Formulation and Evaluation of Moxifloxacin Dry Powder Inhaler Combined with Mucolytic Agent for Pulmonary Diseases

The DPI is the device that administers the drug through the dry powder to the lungs. People with Multi-drug resistant tuberculosis or other lung diseases frequently use such devices to take their prescribed medicines. Numerous approaches have been used to formulate dry powder inhalation formulation and enhance the delivery performance of dry powder inhaler preparation. In the case of multi-drug resistance tuberculosis, a high dose of combination therapy was delivered, resulting in resistance to the anti-TB medications in the majority of patients. Moxifloxacin and levofloxacin are being used to minimize the need for a high-dose treatment regimen. This study aimed to achieve local lung administration of tumor-targeting Moxifloxacin, by administering microspheres that can be inhaled as a dry powder inhaler for targeting Phagocytes of alveoli via pulmonary passage. Spray drying had been used to formulate MXN-DPI formulations, afterward optimized with the 23-factorial design model. Two different amounts of lactose, leucine, and medication were used to make the eight batches. The developed formulation was studied for physicochemical properties like morphology and particle size. The particle dimensions of the MXN-DPI compositions have been confirmed to be in the range of 1.4 to 4.1 μm. The prepared formulations effectively showed drug release up to 93% in 5 hours, which was observed through in-vitro diffusion studies.